WS6是促_beta_细胞增生的新型小分子，在啮齿类动物和人源原发性胰岛中EC50值为0.28uM。

WS6 is a novel small molecule that promotes β cell proliferation in rodent and human primary islets with EC50 of 0.28 uM(R7T1 cell viability). EC50 value: 0.28 uM [1] Target: β cell proliferation agonist in vitro: WS6 induced up to 4% of rat β cells to proliferate, with an EC50 of 0.4 μM. In the same format, WS6 also induced 3% of human β cells to proliferate, with a similar potency to the rat β cells. WS6 induced R7T1 proliferation in dose response, with EC50 value of 0.28 μM, Proliferation of R7T1 cells, which are cultured in suspension and grow as clusters, was apparent by visible inspection. in vivo: RIP-DTA mice were fed Dox in the drinking water until the onset of overt diabetes (blood glucose reading >300 mg/dL, typically 4-10 days), at which point Dox treatment was discontinued and treatment with WS6 was initiated (5 mg/kg every other day via intraperitoneal injection). Pharmacokinetic studies with WS6 at

Solid

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Shen W, et al. Small-molecule inducer of β cell proliferation identified by high-throughput screening. J Am Chem Soc. 2013 Feb 6;135(5):1669-72.
[2]. Zhang H, Xiang L, Yang L, et al. WS6 Induces Adult Hippocampal Neurogenesis in Correlation to its Antidepressant Effect on the Alleviation of Depressive-like Behaviors of Rats. Neuroscience. 2021;473:119-129.

In Vitro: DMSO : ≥ 100 mg/mL (175.87 mM)配制储备液